EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Liquid Biopsy for Glioma Using Cell-Free DNA in Cerebrospinal Fluid

Ryosuke Otsuji iD, Yutaka Fujioka, Nobuhiro Hata, Daisuke Kuga, Ryusuke Hatae, Yuhei Sangatsuda, Akira Nakamizo iD, Masahiro Mizoguchi, Koji Yoshimoto

Cancers · 29.02.2024 · 16 (5) · 1009

DOI: 10.3390/cancers16051009 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 29.02.2024. Verfasst von Ryosuke Otsuji und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 189 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japanese Society for the Promotion of Science Grants-in-Aid for Scientific Research (JSPS KAKENHI) Award, Fukuoka Public Health Promotion Organization Cancer Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioma is one of the most common primary central nervous system (CNS) tumors, and its molecular diagnosis is crucial. However, surgical resection or biopsy is risky when the tumor is located deep in the brain or brainstem. In such cases, a minimally invasive approach to liquid biopsy is beneficial. Cell-free DNA (cfDNA), which directly reflects tumor-specific genetic changes, has attracted attention as a target for liquid biopsy, and blood-based cfDNA monitoring has been demonstrated for other extra-cranial cancers. However, it is still challenging to fully detect CNS tumors derived from cfDNA in the blood, including gliomas, because of the unique structure of the blood–brain barrier. Alternatively, cerebrospinal fluid (CSF) is an ideal source of cfDNA and is expected to contribute significantly to the liquid biopsy of gliomas. Several successful studies have been conducted to detect tumor-specific genetic alterations in cfDNA from CSF using digital PCR and/or next-generation sequencing. This review summarizes the current status of CSF-based cfDNA-targeted liquid biopsy for gliomas. It highlights how the approaches differ from liquid biopsies of other extra-cranial cancers and discusses the current issues and prospects.

Schlagwörter

Stichwörter der Autor:innen

cell-free DNAcerebrospinal fluiddigital PCRgliomaliquid biopsynext-generation sequencing

Autor:innen und Institutionen

  • Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan.
  • Department of Neurosurgery, Oita University Faculty of Medicine, Yufu 879-5593, Japan.
  • Department of Neurosurgery, National Hospital Organization Kyushu Medical Center, Clinical Research Institute, Fukuoka 810-8563, Japan.

ORCID-Profile: Ryosuke Otsuji, Akira Nakamizo

Förderung

  • Japanese Society for the Promotion of Science Grants-in-Aid for Scientific Research (JSPS KAKENHI) Award
  • Fukuoka Public Health Promotion Organization Cancer Research Fund

Zitieren

APA

Otsuji, R., Fujioka, Y., Hata, N., Kuga, D., Hatae, R., Sangatsuda, Y., Nakamizo, A., Mizoguchi, M., & Yoshimoto, K. (2024). Liquid Biopsy for Glioma Using Cell-Free DNA in Cerebrospinal Fluid. Cancers, 16(5), 1009. https://doi.org/10.3390/cancers16051009

Vancouver

Otsuji R, Fujioka Y, Hata N, Kuga D, Hatae R, Sangatsuda Y, et al. Liquid Biopsy for Glioma Using Cell-Free DNA in Cerebrospinal Fluid. Cancers. 2024;16(5):1009. doi:10.3390/cancers16051009

BibTeX
@article{Otsuji2024,
  author = {Otsuji, Ryosuke and Fujioka, Yutaka and Hata, Nobuhiro and Kuga, Daisuke and Hatae, Ryusuke and Sangatsuda, Yuhei and Nakamizo, Akira and Mizoguchi, Masahiro and Yoshimoto, Koji},
  title = {Liquid Biopsy for Glioma Using Cell-Free DNA in Cerebrospinal Fluid},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {5},
  pages = {1009},
  doi = {10.3390/cancers16051009}
}
Kostenlos starten →